Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) FCF Margin (2016 - 2025)

Historic FCF Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to 1.01%.

  • Ascendis Pharma A's FCF Margin rose 972600.0% to 1.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.16%, marking a year-over-year increase of 399600.0%. This contributed to the annual value of 75.46% for FY2024, which is 781300.0% up from last year.
  • Per Ascendis Pharma A's latest filing, its FCF Margin stood at 1.01% for Q3 2025, which was up 972600.0% from 4.64% recorded in Q2 2025.
  • Ascendis Pharma A's 5-year FCF Margin high stood at 1.01% for Q3 2025, and its period low was 10921.62% during Q2 2021.
  • In the last 5 years, Ascendis Pharma A's FCF Margin had a median value of 257.62% in 2023 and averaged 1881.93%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -76757200bps in 2021, then surged by 89627400bps in 2022.
  • Ascendis Pharma A's FCF Margin (Quarter) stood at 194.97% in 2021, then crashed by -209bps to 602.33% in 2022, then skyrocketed by 98bps to 14.05% in 2023, then crashed by -100bps to 28.12% in 2024, then skyrocketed by 104bps to 1.01% in 2025.
  • Its FCF Margin stands at 1.01% for Q3 2025, versus 4.64% for Q2 2025 and 14.18% for Q1 2025.